Learning Objectives
- State the role of both prescription and illicit opioids within osteopathic care.
- Discover the appropriate circumstances for prescribing full agonist opioids for chronic pain, guided by osteopathic philosophy.
- Analyze case studies to identify opportunities for using Buprenorphine and Methadone in the treatment of chronic pain or Opioid Use Disorder (OUD).
- Evaluate the skills in early detection of OUD by learning tools and techniques for assessment.
- Assess the risk/benefit profiles of starting, stopping, or modifying opioid prescriptions for pain management.
- Develop tailored treatment plans for patients with pain or OUD to include the significance of continuous management and support, and incorporate a range of treatment options such as medication-assisted treatment, behavioral therapies, and support services.
Disclosure Statements
ACOFP and ACOI are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of an ineligible company. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACOFP and ACOI require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients). Individuals in a position to control the content may include, but are not limited to, planning committee members, authors, faculty, speakers, reviewers, and activity staff.
ACOFP and ACOI review all disclosed relationships to determine which are relevant and then work with the applicable contributors to mitigate the relevant financial relationships.
No relevant financial relationships were identified for any individual in control of content for this specific activity series.
CME Credit and Designation Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Osteopathic Family Physicians (ACOFP) and American College of Osteopathic Internists (ACOI). ACOFP is accredited by the ACCME to provide continuing medical education for physicians.
ACOFP designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
ACOFP is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
ACOFP designates this enduring activity for a maximum of 1.5 AOA Category 1-A credits and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program.
As an accredited organization named in section 1263 of CAA 2023, ACOFP and ACOI have developed this series that may satisfy all or portions of your DEA training requirements.
Support Acknowledgement
The activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Disclaimer
ACOFP and ACOI present this information for educational purposes only. The content is provided solely by individuals who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ACOFP, ACOI, and the supporter assume no liability for the information herein.
ACOFP is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
ACOFP designates this enduring activity for a maximum of 1.5 AOA Category 1-A credits and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program.
As an accredited organization named in section 1263 of CAA 2023, ACOFP and ACOI have developed this series that may satisfy all or portions of your DEA training requirements.
Support Acknowledgement
The activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Disclaimer
ACOFP and ACOI present this information for educational purposes only. The content is provided solely by individuals who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ACOFP, ACOI, and the supporter assume no liability for the information herein.